The market for Osteoporosis Drugs Market is expected to reach USD XX Mn By 2025.
Osteoporosis is a common disease characterized by porous bone structure, lower bone mass, and reduced bone strength. Osteoporosis is a condition where the regrowth of bone is slower than the breakage of a bone. It is estimated that worldwide, around 200 million people are affected by osteoporosis, which causes around 9 million fractures annually, which is a major public concern as the estimated cost of osteoporosis is about $19 billion in the United States alone. Women are more susceptible to osteoporosis than men due to their thinner bones, according to the International Osteoporosis Foundation.
Estrogen helps maintain bone structure; therefore, women at their menopausal stage are mostly get affected by osteoporosis. Geriatric populations are more likely to develop osteoporosis due to loss of bone minerals. Some of the risk factors for developing osteoporosis include an insufficient diet, a physically inactive lifestyle, smoking, drinking alcohol, a previous family history, and long-term use of steroids.
Rising geriatric and postmenopausal women, increasing prevalence of osteoporosis in younger populations, increased risk of hip, forearm, and spine fractures, and increasing R&D expenditures for new and innovative drug formulations are critical driving forces in the osteoporosis drugs market, while side-effects and adverse reactions of osteoporotic drugs, issues in regulatory approval for drugs, and lower public awareness restrain the market growth.
North America is expected to hold the major share of the osteoporosis drugs market, followed by the European market, due to its well-organized healthcare infrastructure, healthcare expenditure for R&D, and rising health awareness among the public. Asia-Pacific is anticipated to show higher growth due to its large population and growing health awareness.
Global Osteoporosis Drugs Market Revenue (US$ Mn), 2015-2025, By Drug Class
Global Osteoporosis Drugs Market Revenue (US$ Mn), 2015-2025, By Geography
North America
Asia-Pacific
Latin America
Middle East and Africa
A few major players in the osteoporosis drugs market include Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Amgen, Inc., Novo Nordisk A/S, and Actavis Plc. Pfizer, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd., and others
The market for Osteoporosis Drugs Market is expected to reach USD XX Mn By 2025.
The Osteoporosis Drugs Market is expected to see significant CAGR growth over the coming years, at XX%.
The report is forecasted from 2015-2025.
The base year of this report is 2014.
Eli Lilly and Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Amgen, Inc., Novo Nordisk A/S, and Actavis Plc. Pfizer, Inc., GlaxoSmithKline plc., Teva Pharmaceutical Industries Ltd are some of the major players in the global market.